Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Peripheral extracellular vesicles for diagnosis and prognosis of resectable lung cancer: the LUCEx study protocol

  • Rodríguez-Sanz, Jorge
  • Muñoz-González, Nadia
  • Cubero, José Pablo
  • Ordoñez, Pablo
  • Gil, Victoria
  • Langarita, Raquel
  • Ruiz, Myriam
  • Forner, Marta
  • Marín-Oto, Marta
  • Vera, Elisabet
  • Baptista, Pedro
  • Polverino, Francesca
  • Domingo, Juan Antonio
  • García-Tirado, Javier
  • Marin, José María
  • Sanz-Rubio, David
Background/Objectives: Lung cancer is the primary cause of cancer-related deaths. Most patients are typically diagnosed at advanced stages. Low-dose computed tomography (LDCT) has been proven to reduce lung cancer mortality, but screening programs using LDCT are associated with a high number of false positives and unnecessary thoracotomies. It is therefore imperative that a certain diagnosis is refined, especially in cases of solitary pulmonary nodules that are difficult to technically access for an accurate preoperative diagnosis. Extracellular vesicles (EVs) involved in intercellular communication may be an innovative biomarker for diagnosis and therapeutic strategies in lung cancer, regarding their ability to carry tumor-specific cargo. The aim of the LUCEx study is to determine if extracellular vesicle cargoes from both lung tissue and blood could provide complementary information to screen lung cancer patients and enable personalized follow-up after the surgery. Methods: The LUCEx study is a prospective study aiming to recruit 600 patients with lung cancer and 50 control subjects (false positives) undergoing surgery after diagnostic imaging for suspected pulmonary nodules using computed tomography (CT) scans. These patients will undergo curative surgery at the Department of Thoracic Surgery of the Miguel Servet Hospital in Zaragoza, Spain, and will be followed-up for at least 5 years. At baseline, samples from both tumor distal lung tissue and preoperative peripheral blood will be collected and processed to compare the quantity and content of EVs, particularly their micro-RNA (miRNA) cargo. At the third and fifth years of follow-up, CT scans, functional respiratory tests, and blood extractions will be performed. Discussion: Extracellular vesicles and their miRNA have emerged as promising tools for the diagnosis and prognosis of several diseases, including cancer. The LUCEx study, based on an observational clinical cohort, aims to understand the role of these vesicles and their translational potential as complementary tools for imaging diagnosis and prognosis.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Unveiling the therapeutic potential of phenolic compounds from Boletus edulis in osteoarthritis treatment

  • Paesa, Mónica
  • Izquierdo, Mauricio David
  • Remírez de Ganuza, Cristina
  • Ferreira-Santos, Pedro
  • Rodríguez-Yoldi, María Jesús
  • Mendoza, Gracia
Osteoarthritis (OA) is a joint disease characterized by inflammation, cartilage degeneration, and pain. Recent studies have focused on the potential of active phenolic compounds as a treatment for OA, owing to their anti-inflammatory, antioxidant, and chondroprotective effects. Specifically, Boletus edulis (BE) extracts, a natural product from mushrooms, have been shown as significantly active compounds against oxidative stress and inflammation. Our aim was to evaluate the anti-inflammatory and chondroprotective potential of BE extracts, primarily composed of phenolic compounds and flavonoids, in OA in vitro models. Our results showed that cell treatment with 250 µg/mL of BE extracts maintained cell viability above 70% without affecting apoptosis or cell cycle. At the molecular level, BE extracts exerted anti-inflammatory effects by reducing nitric oxide (NO) levels, as well as the expression of inducible nitric oxide synthase (iNOS) and pro-inflammatory cytokines and chemokines (interleukin-6 (IL-6), IL-8, (C-X-C motif) ligand 1 (CXCL-1)) in lipopolysaccharide (LPS)-stimulated cells. Additionally, BE extracts treatment demonstrated a significant decrease in matrix metalloproteinases 3 and 13 (MMP-3, MMP-13) expression, while avoiding the depletion in the expression of chondrogenic markers, aggrecan and collagen II. Furthermore, inflammation was also significantly reduced through the inhibition of p65 nuclear translocation. These findings suggest that BE extracts may provide a promising basis for the development of novel therapeutic strategies in the treatment of OA, reducing inflammation and chondrocytes damage.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Exosomal biomarkers and therapeutics in lung cancer: a narrative review on their role in early detection and targeted treatment

  • Rodríguez-Sanz, Jorge
  • Mincholé Lapuente, Elisa
  • Polanco Alonso, Dinora
  • Viñuales Aranda, Manuel David
  • Marín-Oto, Marta
  • Domingo Morera, Juan Antonio
  • Marín Trigo, José María
  • Sanz-Rubio, David
Background and Objective: Lung cancer remains the leading cause of cancer-related mortality worldwide, largely due to late-stage diagnosis and therapy resistance. Despite advances in targeted therapies and immunotherapies, the prognosis remains poor. There is a critical need for minimally invasive biomarkers that enable early detection, prognostic stratification and therapeutic monitoring. Exosomes, a subtype of extracellular vesicles, have emerged as promising candidates in this context given their role in intercellular communication and their selective cargo, which reflects the molecular state of tumor cells. This review aims to summarize the current evidence on the potential of exosomes and their cargo, particularly microRNAs (miRNAs), as diagnostic and prognostic biomarkers as well as therapeutic tools in lung cancer. Methods: A comprehensive literature search was conducted using PubMed/MEDLINE and Scopus databases between January 3 and April 30, 2025. Studies published from January 2000 to April 2024 were included if they addressed the role of exosomes in lung cancer diagnosis, prognosis, or therapy. Two reviewers independently screened titles and abstracts and full texts were assessed based on predefined inclusion criteria. Relevant articles were also identified through reference lists. Key Content and Findings: Exosomal miRNAs (microRNAs) have shown potential as biomarkers for early detection, disease subtype classification, prognosis and therapy resistance in lung cancer. Multiple studies have identified specific miRNA signatures associated with tumor burden, histological subtypes and clinical outcomes. Exosomes also contribute actively to oncogenesis through promoting angiogenesis, epithelial-mesenchymal transition, immune evasion and drug resistance. Furthermore, exosomes are being investigated both as therapeutic targets and delivery systems due to their ability to transfer functional biomolecules selectively and safely. Despite these advances, challenges remain regarding standardization of isolation methods, heterogeneity in miRNA signatures and clinical validation. Conclusions: Exosomes represent a dynamic and promising platform for improving the diagnosis, prognosis and treatment of lung cancer. Although technical and translational hurdles remain, their integration into clinical practice may enhance personalized and precision oncology strategies. Continued research and technological advancements are necessary to fully unlock their potential in routine cancer care.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Exploring the anti-inflammatory effects of genistein in an in vitro lipopolysaccharide-induced macrophage model

  • Remirez de Ganuza, Cristina
  • López, Sonia
  • Mendoza, Gracia
Inflammation plays a central role in the onset and progression of numerous diseases, and macrophages are key regulators of this process through their polarization toward pro- or anti-inflammatory phenotypes. Natural bioactive compounds have emerged as promising candidates to modulate inflammatory responses. Amongst these, genistein, a soybean-derived isoflavone, was selected due to its reported anti-inflammatory and antioxidant profile across different cell types. In this study, we evaluated the effects of genistein in a lipopolysaccharide (LPS)-induced macrophage model to investigate its cellular and molecular mechanisms of action. Genistein treatment at subcytotoxic concentration preserved cell viability, did not induce apoptosis or cell cycle arrest, and reduced oxidative stress. In LPS-stimulated macrophages, treatment with 5 µg/mL genistein significantly decreased nitric oxide production and downregulated pro-inflammatory markers while upregulating an anti-inflammatory mediator, thus reverting macrophage polarization to an anti-inflammatory phenotype. Protein analyses confirmed reduced expression of iNOS and cytokines such as IL-6 and TNF-α. Furthermore, genistein restored cell morphology and inhibited NF-κB p65 nuclear translocation, indicating its capacity to counteract LPS-driven pro-inflammatory signalling. These findings support the role of genistein in modulating macrophage polarization and inflammatory responses, highlighting its therapeutic potential for the management of acute and chronic inflammation-related disorders.